Seegene has emphasized the necessity of comprehensive testing that simultaneously detects sexually transmitted infections (STIs) and human papillomavirus (HPV). The company argues that due to the prevalence of asymptomatic infections and the similarity of symptoms across pathogens, relying solely on tests for individual diseases is insufficient for accurately identifying genital infections.
On July 27, the global molecular diagnostics company highlighted the clinical utility of its syndromic PCR-based reproductive tract infection (RTI) comprehensive test.
The company has accumulated real clinical data through its 'Global Million Clinical Study (GMCS),' announced on July 8. Based on this data, Seegene aims to validate the clinical value of disease-specific tests and establish a scientific basis for new global testing standards.
HPV is recognized as a major cause of cervical cancer. Particularly, high-risk genotypes, including HPV types 16 and 18, are closely linked to the development of cervical cancer, making it crucial to identify not just the presence of infection but also the specific genotypes detected. Consequently, screening and follow-up strategies may vary based on the genotype, according to the company.
STIs can be caused by various pathogens, including chlamydia and gonorrhea, and present a range of symptoms such as abnormal discharge, painful urination, genital pain and itching, dyspareunia, lower abdominal pain, ulcers, vesicles, and warts. However, the similarity of symptoms across pathogens makes it difficult to pinpoint the cause based solely on symptoms, and the presence of asymptomatic infections increases the risk of unnoticed transmission.
Using its real-time testing data analysis platform, STAgora, Seegene recently analyzed approximately 60,000 simultaneous HPV and STI test results generated over three and a half years. The analysis revealed that 82% of HPV-positive cases detected 28 types of HPV also had STI pathogens present, while 46% of STI-positive cases also confirmed the presence of HPV. Among comprehensive test positive cases that included both HPV and STIs, 71% showed concurrent detection.
Seegene interprets these findings as evidence of the utility of STI co-testing in the HPV screening process. The company notes that this approach could be beneficial for identifying asymptomatic STIs, assessing co-infections in HPV-positive patients, and monitoring reproductive health during pregnancy preparation and infertility evaluations.
Seegene stated, "Through GMCS, we plan to continuously secure clinical results for the HPV and STI comprehensive test and validate its clinical utility and applicability using STAgora-based statistics."
On July 27, the global molecular diagnostics company highlighted the clinical utility of its syndromic PCR-based reproductive tract infection (RTI) comprehensive test.
The company has accumulated real clinical data through its 'Global Million Clinical Study (GMCS),' announced on July 8. Based on this data, Seegene aims to validate the clinical value of disease-specific tests and establish a scientific basis for new global testing standards.
HPV is recognized as a major cause of cervical cancer. Particularly, high-risk genotypes, including HPV types 16 and 18, are closely linked to the development of cervical cancer, making it crucial to identify not just the presence of infection but also the specific genotypes detected. Consequently, screening and follow-up strategies may vary based on the genotype, according to the company.
STIs can be caused by various pathogens, including chlamydia and gonorrhea, and present a range of symptoms such as abnormal discharge, painful urination, genital pain and itching, dyspareunia, lower abdominal pain, ulcers, vesicles, and warts. However, the similarity of symptoms across pathogens makes it difficult to pinpoint the cause based solely on symptoms, and the presence of asymptomatic infections increases the risk of unnoticed transmission.
Using its real-time testing data analysis platform, STAgora, Seegene recently analyzed approximately 60,000 simultaneous HPV and STI test results generated over three and a half years. The analysis revealed that 82% of HPV-positive cases detected 28 types of HPV also had STI pathogens present, while 46% of STI-positive cases also confirmed the presence of HPV. Among comprehensive test positive cases that included both HPV and STIs, 71% showed concurrent detection.
Seegene interprets these findings as evidence of the utility of STI co-testing in the HPV screening process. The company notes that this approach could be beneficial for identifying asymptomatic STIs, assessing co-infections in HPV-positive patients, and monitoring reproductive health during pregnancy preparation and infertility evaluations.
Seegene stated, "Through GMCS, we plan to continuously secure clinical results for the HPV and STI comprehensive test and validate its clinical utility and applicability using STAgora-based statistics."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.